Genetic determinants of aggressive breast cancer

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 199-212

  Ventura, Alejandra C ^a,b   Merajver, Sofia D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomarker; Drug target; Genetic marker; Inflammatory breast cancer

Indexed keywords

BIOLOGICAL MARKER;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GENETICS; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MARKER; HUMAN; LETHALITY; PRIORITY JOURNAL; REVIEW;

BREAST NEOPLASMS; FEMALE; GENETIC MARKERS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 39649105682     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.060106.184830     Document Type: Review

References (70)

1. Vogelstein B, Kinzler KW. 1998. The Genetic Basis of Human Cancer. McGraw-Hill
2. Dalton WS, Friend SH. 2006. Cancer biomarkers - an invitation to the table. Science 312:1165-68
3. Benson JD, Chen YC, Cornell-Kennon SA, et al. 2006. Validating cancer drug targets. Nature 441:451-56
4. Sears C, Armstrong SA. 2007. Microarrays to identify new therapeutic strategies for cancer. Adv. Cancer Res. 96:51-74
5. Ridley A. 2000. Molecular switches in metastasis. Nature 406(6795):466-67
6. Varmus H. 2006. The new era in cancer research. Science 312(5777):1162-65
7. Sawyers C. 2004. Targeted cancer therapy. Nature 432(7015):294-97
8. Hornberg JJ, Bruggeman FJ, Westerhoff HV, et al. 2006. Cancer: a systems biology disease. Biosystems 83(2-3):81-90
9. Stocks LH, Patterson FM. 1976. Inflammatory carcinoma of the breast. Surg. Gynecol. Obstet. 143:885-89
10. Levine PH, Steinhorn SC, Ries LG, et al. 1985. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J. Natl. Cancer Inst. 74:291-97
11. Kleer CG, van Golen KL, Merajver SD. 2000. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2(6):423-29
12. Merajver SD, Weber BL, Cody R, et al. 1997. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J. Clin. Oncol. 15(8):2873-81
13. 12a. Low J, Berman A, Steinber S, et al. 2004. Long term follow up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J. Clin. Oncol. 22:4065-74
14. Cristofanilli M, Gonzalez-Anugulo AM, Buzdar AU, et al. 2004. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M.D. Anderson Cancer Center experience. Clin. Breast Cancer 4:415-19
15. Lee BJ, Tannenbaum ND. 1924. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg. Gynecol. Obstet. 39:580-95
16. Giordano SH, Hortobagyi GN. 2003. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res. 5(6):284-28
17. van Golen KL, Davies S, Wu ZF, et al. 1999. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin. Cancer Res. 5(9):2511-19
18. van Golen KL, Wu ZF, Qiao XT, et al. 2000. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 60(20):5832-38
19. Ethier SP. 1996. Human breast cancer cell lines as models of growth regulation and disease progression. J. Mammary Gland Biol. Neoplasia 1:111-21
20. Kaufman M. 2000. Review of known prognostic variables. Results Probl. Cell Differ. 140:77-87
21. Slamon DJ, Godolphin W, Jones LA, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-12
22. Feki A, Irminger-Finger I. 2004. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52:103-16
23. Moll UM, Riou G, Levine PH. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89:7262-66
24. Riou G, Le MG, Travagli JP, et al. 1993. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J. Natl. Cancer Inst. 85:1765-67
25. Gonzalez-Angulo AM, Sneige N, Kau SW, et al. 2004. p53 expression as a prognostic marker in inflammatory breast cancer. Clin. Cancer Res. 10:6215-21
26. Peinado H, Portillo F, Cano A. 2004. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 48:365-75
27. Kleer CG, van Golen K, Braun T, et al. 2001. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol. 14:458-64
28. Gamallo C, Palacios J, Suarez A, et al. 1993. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol. 142:987-93
29. Oka H, Shiozaki H, Kobayashi K, et al. 1993. Expression of E-cadherin cell adhesion molecule in human breast cancer tissues and its relationship to metastasis. Cancer Res. 53:1696-701
30. Tomlinson JS, Alpaugh ML, Barsky SH. 2001. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 61:5231-41
31. Charafe-Jauffret E, Tarpin C, Bardou V-J, et al. 2004. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J. Pathol. 202:265-73
32. Achen M, Jeltsch M, Kukk E, et al. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flt 1) and VEGF receptor 3 (Flt 4). Proc. Natl. Acad. Sci. USA 95:548-53
33. Kurebayashi J, Ostuski T, Kunisue H, et al. 1999. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. J. Cancer Res. 90:977-81
34. Ridley A. 1997. The GTP-binding protein Rho. Int. J. Biochem. Cell Biol. 29:1225-29
35. Etienne-Manneville S, Hall A. 2002. Rho GTPases in cell biology. Nature 420:629-35
36. Sahai E, Marshall CJ. 2002. Rho-GTPases and cancer. Nat. Rev. Cancer 2:133-42
37. Wagner AC, Williams JA. 1994. Low molecular weight GTP-binding proteins: molecular switches regulating diverse cellular functions. Am. J. Physiol. 266:G1-14
38. Yao H, Dashner EJ, van Golen CM, et al. 2006. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 25(16):2285-96
39. Coleman ML, Marshall CJ, Olson MF. 2004. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol. 5(5):355-66
40. Burbelo P, Wellstein A, Pestell RG. 2004. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res. Treat. 84:43-48
41. Wheeler AP, Ridley AJ. 2004. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. 301:43-49
42. Van Den Eynden GG, Van Der Auwera I, Van Laere S, et al. 2004. Validation of a tissue microarray to study differential protein expression in inflammatory and noninflammatory breast cancer. Breast Cancer Res. Treat. 85:13-22
43. Kleer CG, van Golen KL, Zhang Y, et al. 2002. Characterization of RhoC expression in benign and malignant breast disease - a potential new marker for small breast carcinomas with metastatic ability. Am. J. Pathol. 160:579-84
44. Kleer CG, Griffith KA, Sabel MS, et al. 2005. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res. Treat. 93:101-10
45. Kamai T, Tsujii T, Arai K, et al. 2003. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9:2632-41
46. Horiuchi A, Imai T, Wang C, et al. 2003. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab. Invest. 83:861-70
47. Suwa H, Ohshio G, Imamura T, et al. 1998. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer 77:147-52
48. Clark EA, Golub TR, Lander ES, et al. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-35
49. Wang W, Yang LY, Huang GW, et al. 2004. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br. J. Cancer 90:2349-55
50. Hakem A, Sanchez-Sweatman O, You-Ten A, et al. 2005. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 19:1974-79
51. van Golen KL, Wu ZF, Qiao XT, et al. 2000. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2:418-25
52. Wu M, Wu ZF, Kumar-Sinha C, et al. 2004. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res. Treat. 84:3-12
53. Perbal B. 2001. The CCN family of cell growth regulators: a new family of normal and pathologic cell growth and differentiation regulators: lessons from the first international workshop on CCN gene family. Bull. Cancer 88:645-49
54. Hurvitz JR, Suwairi WM, Van Hul W, et al. 1999. Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat. Genet. 23:94-98
55. Pennica D, Swanson TA, Welsh JW, et al. 1998. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. USA 95:14717-22
56. Perbal B, Martinerie C, Sainson R, et al. 1999. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc. Natl. Acad. Sci. USA 96:869-74
57. Moschos SJ, Mantzoros CS. 2002. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63:317-32
58. Sprenger CC, Damon SE, Hwa V, et al. 1999. Insulin-like growth factor binding protein related protein 1 (IGFBP-rP1) is a potential tumor suppressor for prostate cancer. Cancer Res. 59:2370-75
59. Burger A, Zhang X, Li H, et al. 1998. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 16:2459-67
60. Kleer CG, Zhang Y, Pan Q, et al. 2002. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21(20):3172-80
61. Kleer CG, Zhang Y, Pan Q, et al. 2004. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 6(2):R110-15
62. Deleted in proof
63. Zhang Y, Pan Q, Zhong H, et al. 2 005. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res. 7(6):R1080-89
64. Wu M, Merajver SD. 2006. Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis. 22:25-34
65. Sebti SM, Hamilton AD. 2000. Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors. Methods Enzymol. 325:381-88
66. Adamson P, Marshall CJ, Hall A, et al. 1992. Post-translational modifications of p21rho proteins. J. Biol. Chem. 267(28):20033-38
67. Seabra MC. 1998. Membrane association and targeting of prenylated Ras-like GTPases. Cell. Signal. 10(3):167-72
68. Lebowitz PF, Davide JP, Prendergast GC. 1995. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15(12):6613-22
69. Liu A, Du W, Liu JP, et al. 2000. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 20(16):6105-13
70. van Golen KL, Bao L, DiVito MM, et al. 2002. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol. Cancer Ther. 1(8):575-83